BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lee JW, Kulasekararaj AG. Ravulizumab for the treatment of paroxysmal nocturnal hemoglobinuria. Expert Opin Biol Ther 2020;20:227-37. [PMID: 32011183 DOI: 10.1080/14712598.2020.1725468] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
2 Caetano R, Cordeiro Dias Villela Correa M, Villardi P, Almeida Rodrigues PH, Garcia Serpa Osorio-de-Castro C. Dynamics of patents, orphan drug designation, licensing, and revenues from drugs for rare diseases: The market expansion of eculizumab. PLoS One 2021;16:e0247853. [PMID: 33667235 DOI: 10.1371/journal.pone.0247853] [Reference Citation Analysis]
3 Lee SE, Lee JW. Safety of current treatments for paroxysmal nocturnal hemoglobinuria. Expert Opin Drug Saf 2021;20:171-9. [PMID: 33249943 DOI: 10.1080/14740338.2021.1857723] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
4 Doll H, Coşkun U, Hartford C, Tomazos I. Concept confirmation of the Treatment Administration Satisfaction Questionnaire (TASQ) in rare paroxysmal nocturnal hemoglobinuria. J Patient Rep Outcomes 2021;5:45. [PMID: 34152498 DOI: 10.1186/s41687-021-00319-9] [Reference Citation Analysis]
5 Barratt J, Weitz I. Complement Factor D as a Strategic Target for Regulating the Alternative Complement Pathway. Front Immunol 2021;12:712572. [PMID: 34566967 DOI: 10.3389/fimmu.2021.712572] [Reference Citation Analysis]